CGTX News and Press, Cognition Therapeutics Inc.

PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi , has been invited to participate in a fireside...

2026-06-26 10:07:20 ET ... Read the full article on Seeking Alpha For further details see: Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

A look at the top 10 most actives in the United States Aditxt Inc. (ADTX) fell 77.2% to $0.0095 on volume of 4,419,910,909 shares GD Culture Group Limited (GDC) rose 3.3% to $0.0216 on volume of 1,264,025,355 shares Direxion Daily Semiconductor Bear 3X (SOXS) rose 1.0% to $4.08 on volume of...

A look at the top 10 most actives in the United States Aditxt Inc. (ADTX) rose 33.1% to $0.0555 on volume of 644,698,315 shares GD Culture Group Limited (GDC) fell 15.3% to $0.0177 on volume of 395,880,007 shares Hyperscale Data Inc. (GPUS) rose 9.1% to $0.279 on volume of 252,827,807 share...

2026-06-24 08:06:21 ET More on Cognition Therapeutics Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cognition Therapeutics Historical earnings data for Cognition Therapeutics Financial information ...

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the "Company" or "Cognition") (NASDAQ: CGTX)...

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received fro...

PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at two financial conference...

- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the &#x...

PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic donation has been recei...